Inari Medical, Inc. (NASDAQ:NARI) Shares Sold by Amalgamated Bank

Amalgamated Bank trimmed its position in shares of Inari Medical, Inc. (NASDAQ:NARI) by 6.3% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 14,870 shares of the company’s stock after selling 1,001 shares during the period. Amalgamated Bank’s holdings in Inari Medical were worth $613,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Bessemer Group Inc. lifted its stake in shares of Inari Medical by 16.4% in the 1st quarter. Bessemer Group Inc. now owns 2,439 shares of the company’s stock valued at $117,000 after purchasing an additional 344 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its position in Inari Medical by 7.7% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 4,852 shares of the company’s stock worth $234,000 after purchasing an additional 348 shares in the last quarter. Arizona State Retirement System raised its holdings in Inari Medical by 2.5% in the second quarter. Arizona State Retirement System now owns 14,602 shares of the company’s stock valued at $703,000 after buying an additional 358 shares during the period. Covestor Ltd lifted its position in Inari Medical by 30.2% during the first quarter. Covestor Ltd now owns 1,619 shares of the company’s stock valued at $78,000 after buying an additional 376 shares in the last quarter. Finally, Nisa Investment Advisors LLC grew its stake in Inari Medical by 83.5% during the second quarter. Nisa Investment Advisors LLC now owns 956 shares of the company’s stock worth $46,000 after buying an additional 435 shares during the period. 90.98% of the stock is owned by hedge funds and other institutional investors.

Inari Medical Stock Performance

Shares of Inari Medical stock opened at $50.56 on Friday. The firm has a market cap of $2.96 billion, a P/E ratio of -37.45 and a beta of 0.96. The firm’s 50-day simple moving average is $45.19 and its 200-day simple moving average is $46.94. Inari Medical, Inc. has a twelve month low of $36.73 and a twelve month high of $67.13.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on NARI shares. William Blair started coverage on Inari Medical in a research report on Thursday, July 25th. They set an “outperform” rating on the stock. Truist Financial boosted their target price on shares of Inari Medical from $46.00 to $50.00 and gave the stock a “hold” rating in a research report on Tuesday, October 29th. Piper Sandler raised their price target on shares of Inari Medical from $50.00 to $52.00 and gave the company a “neutral” rating in a report on Tuesday, October 29th. Leerink Partners began coverage on shares of Inari Medical in a research note on Tuesday, September 3rd. They set a “market perform” rating and a $47.00 price target on the stock. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on shares of Inari Medical in a research report on Friday, August 9th. They issued a “buy” rating and a $68.00 price objective for the company. Six investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $58.89.

Insider Transactions at Inari Medical

In other news, CFO Mitch C. Hill sold 3,000 shares of the stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $45.13, for a total value of $135,390.00. Following the transaction, the chief financial officer now owns 179,600 shares of the company’s stock, valued at $8,105,348. This represents a 1.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director William Hoffman sold 40,000 shares of the company’s stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $45.02, for a total value of $1,800,800.00. Following the completion of the sale, the director now directly owns 601,233 shares of the company’s stock, valued at approximately $27,067,509.66. This trade represents a 6.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 126,000 shares of company stock valued at $5,921,390 in the last three months. 10.60% of the stock is owned by corporate insiders.

Inari Medical Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.